- Home
- CATX vs INNV Comparison
CATX vs INNV Comparison
Compare CATX & INNV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CATX
- INNV
- Stock Information
- Founded
- CATX 1983
- INNV 2007
- Country
- CATX United States
- INNV United States
- Employees
- CATX N/A
- INNV N/A
- Industry
- CATX Medical/Dental Instruments
- INNV Medical/Nursing Services
- Sector
- CATX Health Care
- INNV Health Care
- Exchange
- CATX Nasdaq
- INNV Nasdaq
- Market Cap
- CATX 782.7M
- INNV 817.8M
- IPO Year
- CATX N/A
- INNV 2021
- Fundamental
- Price
- CATX $3.07
- INNV $4.08
- Analyst Decision
- CATX Strong Buy
- INNV Hold
- Analyst Count
- CATX 9
- INNV 3
- Target Price
- CATX $17.25
- INNV $6.00
- AVG Volume (30 Days)
- CATX 2.7M
- INNV 54.0K
- Earning Date
- CATX 11-12-2024
- INNV 02-04-2025
- Dividend Yield
- CATX N/A
- INNV N/A
- EPS Growth
- CATX N/A
- INNV N/A
- EPS
- CATX N/A
- INNV N/A
- Revenue
- CATX $1,557,000.00
- INNV $786,512,000.00
- Revenue This Year
- CATX N/A
- INNV $13.33
- Revenue Next Year
- CATX N/A
- INNV $10.23
- P/E Ratio
- CATX N/A
- INNV N/A
- Revenue Growth
- CATX N/A
- INNV 12.46
- 52 Week Low
- CATX $2.50
- INNV $3.52
- 52 Week High
- CATX $19.10
- INNV $6.69
- Technical
- Relative Strength Index (RSI)
- CATX 20.31
- INNV 21.18
- Support Level
- CATX $3.27
- INNV $4.31
- Resistance Level
- CATX $3.60
- INNV $4.93
- Average True Range (ATR)
- CATX 0.33
- INNV 0.25
- MACD
- CATX 0.21
- INNV -0.03
- Stochastic Oscillator
- CATX 0.00
- INNV 2.56
About CATX Perspective Therapeutics Inc.
Perspective Therapeutics Inc is a medical technology and radiopharmaceutical company that is pioneering various treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting peptides.
About INNV InnovAge Holding Corp.
InnovAge Holding Corp is a healthcare delivery platform by several participants focused on providing all-inclusive, capitated care to high-cost, dual-eligible seniors. Its patient-centered care delivery approach improves the quality of care while keeping them in their homes and reducing over-utilization of high-cost care settings such as hospitals and nursing homes. The company's segment includes PACE and others. It generates maximum revenue from the PACE segment.